39700 Bob Hope Drive , Suite 108, Rancho Mirage, CA 92270      Phone: 760 346 7655
Home  |   About Us   |   Contact   
 
 
      Doctor Resume    |   Our Team    |   Jobs
Chemotherapy Treatment |Patient Support  | Cancer News | Links  | New Patient Registration Packet
TODD YATES, D. O.
 
Office:
Desert Cancer Care, Inc.
39700 Bob Hope Drive,
Bob Hope Classic Medical Bldg,
Suite 108, Rancho Mirage, CA 92270
     
 
Affiliating Institutions:
Eisenhower Medical Center, 39000 Bob Hope Drive, Rancho Mirage, CA 92270
 
Board Certification:
  
 
2005
Diplomate, American Board of Internal Medicine
 
Interests:
Particular interest in Gastrointestinal Cancers (colon, rectal, esophageal, gastric)
 
strong>Licenses:
CALIFORNIA
Basic Life Support/ Advanced Cardiac Life Support
National Board of Osteopathic Medical Examination Step III
National Board of Osteopathic Medical Examination Step II
National Board of Osteopathic Medical Examination Step I
 
POST GRADUATE TRAINING:
 
 
2005 – 2008
Fellowship, Department of Hematology/Oncology
Henry Ford Hospital, Detroit, Michigan
 
2002 - 2005
Residency, Department of Internal Medicine
Henry Ford Hospital, Detroit, Michigan
 
2001 – 2002
Internship, Department of Internal Medicine
Henry Ford Bicounty Hospital, Detroit, Michigan
 
GRADUATE MEDICAL EDUCATION
 
 
1997 - 2006
Chicago College of Osteopathic Medicine
Downers Grove, Illinois
 
EDUCATION
 
 
1993 – 1997
University of Idaho
Moscow, Idaho
B.S. Zoology
 
1989 - 1993
Moscow High School
Moscow, Idaho
     
 
MAJOR PROFESSIONAL SOCIETIES
 
   
American Society of Clinical Oncology
American society of Hematology
American Medical Association
American College of Physicians/American Society of Internal Medicine
 
HONORS AND AWARDS
 
 
Residency:
  
 
10/2004
Finalist Poster Presentation: ACP Michigan Chapter; Annual Scientific Meeting
  05/2004
Second Place Oral Presentation: ACP Michigan Chapter; Associates Day
 
Medical School :
  
 
1997 - 2001
Sigma Sigma Phi Academic Medical Honor Society
 
1997 - 1998
Student Leadership Award, Class Vice President
 
Undergraduate :
  
 
1996 – 1997
Biological Sciences Honor Society
 
996 – 1997
Betsy May Scholarship
 
1995 – 1997
Gritman Medical Center Scholarship
     
 
Publications:
  
 
David C. Bencic, Todd J. Yates, and Rolf L. Ingermann.  1997
“Ecto-ATPase Activity of Vertebrate Blood Cells”.  Journal of Physiological Zoology.  70:6, 621-630.

Yates T, Kuriakose P.  A Case Report on Pulmonary Artery Sarcoma Mimicking a Pulmonary Embolism. Indian Journal of Cancer 2008; 45: 27-29.

Yates Y., Abowjoud M., Lambing A., Kuriakose P.  The Risk of Venous Thrombosis in patients with Primary Versus Secondary Hepatic Malignancies Who are Undergoing Surgical Resection.  Accepted for Publication to Indian Journal of Gastroenterology.
     
 
Oral Presentations
 
 
Sandhu A, Yates T, Kuriakose P. Pulmonary Artery Sarcoma Impersonating a Pulmonary Embolism.  Oral Presentation: ACP-ASIM; Michigan Chapter Scientific Meeting.  September 12, 2006, Traverse City, MI. & ACP National Meeting. April 19, 2007; San Diego CA.

Lingam N, Yates T, Tejwani S. Sudden Demise of a Patient on Capecitabine may be related to Decreased Dihydropyrimidine Dehydrogenase Enzyme Activity. Oral Presentation: ACP-ASIM; Michigan Associates Day Meeting. May 7, 2004, Southfield, MI. Second Place Award.
   
 
Poster Presentations
 
 
Yates T, Lingam N, Jeffries J. The Correlation of Testosterone Levels and Diabetes. Poster Presentation: ACP-ASIM; Michigan Chapter Scientific Meeting. October 1, 2004, Traverse City, MI. Voted as Finalist out of 300 Posters.

Yates T, Maeda K, Kuriakose P.  Eosinphilic Chloroma, A Case Report:  ACP-ASIM;  Michigan Chapter Scientific Meeting. September 12, 2003, Traverse City, MI.

Vatca M, Yates T, Tejwani S.  Ischemic Myositis in a Diabetic Patient who is currently Receiving Chemotherapy.  Society of General Internal Medicine; Regional Midwest Meeting. Chicago, IL  2007.
 

 
Research Experience:
  
 
2008
Sub-Investigator - Novartis Pharmaceuticals Corp: A prospective, Randomized, Multi-Center, 3 arm of the continued efficacy and  safety of Zometa in patients with documented bone metastases from Breast cancer.  Protocol #CZOL446E2352
2008
Principal-Investigator - Amgen Protocol# 20050154:  Phase 2,
Randomized, Double Blind, Placebo-Controlled Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Chemotherapy-Induced Thrombocytopenia In Subject with Advanced Non-Small Cell
Lung Cancer Already Receiving Gemcitabine and Platinum.
2008
Sub-Investigator – GPC Biotech Inc.: Protocol # SAT3-06-04 Expanded Access  Study of Satraplatin Plus Prednisone in Patients with Hormone Refratory Prostate Cancer Previously Treated with Unlimited Cytotoxic Chemotherapy.
2008
Sub-Investigator for Millennium Pharma., : Protocol # C05009:
Phase IIIB, randomized study of three treatment regimens in subjects with previously untreated Multpile Myeloma who are not considered candidates High Dose Chemotherapy and Autologous Stem Cell Transplatation.  Velcade, Thalomide & Dexamethasone (VTD) vs. Velcade and Dexamethasone (VD)
Vs. Velcade, Melphalan, and Prednisone (VMP).
2008
Sub-Investigator – NSABP-B-42:  A Clinical Trial to Determine the Efficacy o Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Follow by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer.
2008
Sub-Investigator - E5103: A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer.
2008
Sub-Investigator - IBCSG-2402:  Phase III Randomized Study of Ovarian Function Suppression in Combination With Tamoxifen Versus Ovarian Function Suppression in Combination With Exemestane Versus Tamoxifen Alone in Premenopausal Women With Endocrine-Responsive Breast Cancer.
2008
Sub-Investigator - E2Z04: Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance.  For patients diagnosed with breast cancer between 18-45 years old or between 55-78 years old and patient received chemotherapy 3-8 years ago and is currently disease free. 
2008
Sub-Investigator - NSABP-B-39: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer. 
2008
Sub- Investigator - S0500: A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-up Assessment.
2008
Sub-Investigator - E5597: Randomized Phase III Chemoprevention Trial of Selenium Supplements in Persons with Resected Stage I NSCLC.
2008
Sub-Investigator - S0421: Phase III Study of Docetaxel and Atrasentan versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer.
2008
Sub-Investigator - RTOG-0521: A Phase III Protocol of Androgen Suppression (AS) and 3DCTR/IMRT vs AS and 3DCTR/IMRT Followed by Chemotherapy With Docetaxel and Prednisone for Localized, High-Risk, Prostate Cancer.
2008
Sub-Investigator - RTOG-0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma. 
2008
Sub-Investigator - N0574-Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in Patients with One to Three Cerebral Metastases.